13 results
6-K
EX-99.2
IFRX
InflaRx N.V.
1 Nov 23
Current report (foreign)
8:04am
reputation, business, financial condition and operating results.
Manufacturing: The manufacturing processes of Gohibic (vilobelimab) is complex. We may … as the result of manufacturing errors, design/labeling defects or other deficiencies, our reputation would be adversely affected.
II-15
Distribution
6-K
EX-99.2
IFRX
InflaRx N.V.
10 Aug 23
Report of Foreign Private Issuer
8:00am
of Gohibic (vilobelimab) is subject to a number of risks that could harm our reputation, business, financial condition and operating results … deficiencies, our reputation would be adversely affected.
Distribution: Gohibic (vilobelimab) is a “cold-chain product” that must be shipped and stored
6-K
m67mejly60izgalctj
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.1
9s4dj 6x4q93v8woj8ix
30 Jun 20
Current report (foreign)
6:38am
20-F/A
cdj 8dxohd
29 Mar 19
Annual report (foreign) (amended)
4:23pm
424B4
n54s03cdtls3b8yycp
7 May 18
Prospectus supplement with pricing info
4:47pm
F-1
37wxccadi5kw0
2 May 18
Registration statement (foreign)
7:10am
20-F
qvrt0
29 Mar 18
Annual report (foreign)
12:00am
- Prev
- 1
- Next